¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Anti Plaque Dent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dental plaque
    Ä¡ÅÂ
  • desmosomal plaque
    °áÇÕÆÇ
  • fibrous plaque
    ¼¶À¯ÆÇ
  • hemolytic plaque
    ¿ëÇ÷ÆÇ, ¿ëÇ÷ÇöóÅ©
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤(¹ý), ¿ëÇ÷ÇöóÅ©ÃøÁ¤(¹ý)
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • hybridization plaque
    Çöóũȥ¼ºÃ¼È­
  • large plaque parapsoriasis
    Å«ÆÇÀ¯»ç°Ç¼±, Å«ÆÇÀ¯»ç¸¶¸¥ºñ´ÃÁõ
  • mottled plaque
    ¹Ý»óÆÇ, Åé´Ï¸ð¾çÇöóÅ©
  • mucous patch plaque
    Á¡¸·ÆÇ
  • plaque
    ÆÇ, ÇöóÅ©
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • plaque morphology mutation
    ÆÇÇüŵ¹¿¬º¯ÀÌ, ÇöóÅ©Çüŵ¹¿¬º¯ÀÌ
  • plaque technique
    ÇöóÅ©(±â)¹ý
  • plaque-forming unit
    ÇöóÅ©Çü¼º´ÜÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dental plaque
    Ä¡¸é¼¼±Õ¸·, Ä¡ÅÂ, Ä¡¾ÆÆÇ
  • desmosomal plaque
    ºÎÂøÆÇ
  • fibrous plaque
    ¼¶À¯ÆÇ
  • hemolytic plaque
    ¿ëÇ÷ÇöóÅ©, ¿ëÇ÷ÆÇ
  • hemolytic plaque test
    ¿ëÇ÷ÇöóÅ©°Ë»ç
  • hybridization plaque
    ÇöóÅ©ºÎÇÕ¹ý
  • mottled plaque
    ¿ë±ÕÆÇ, Åé´Ï¸ð¾çÇöóÅ©
  • mucous patch plaque
    Á¡¸·ÆÇ
  • plaque morphology mutation
    (¢¡plaque-type mutation) ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • plaque
    ÆÇ, ÇöóÅ©
  • phage plaque-forming unit
    ÆÄÁö¿ë±ÕÇü¼º´ÜÀ§, ÆÄÁöÇöóÅ©Çü¼º´ÜÀ§
  • plaque technique
    ÇöóÅ©°Ë»ç¹ý
  • plaque-forming unit
    ÇöóÅ©Çü¼º´ÜÀ§
  • yellow plaque
    Ȳ»öÆÇ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-Sp autoantibody
    Ç×-Sp ÀÚ°¡Ç×ü
  • anti-antidote
    Ç×ÇØµ¶¾à.
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • anti-glomerular,basement menbrane nephritis
    Ç׻籸ü±âÀú¸·½Å¿°(ù÷Þêϳô÷Ðñî¼Ø¯ãìæú)
  • anti-i autoantibody
    Ç×-I ÀÚ°¡Ç×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • anti-immune body
    Ç׸鿪ü.
  • anti-infective
    Ç×°¨¿°¼º, Ç×°¨¿°¾à.
  • anti-infective
    1. Ç×°¨¿°¼º. 2. Ç×°¨¿°¾à.
  • anti-inflammatory
    Ç׿°Áõ¼º(ù÷æúñøàõ)ÀÇ.
  • anti-inflammatory
    Ç׿°(Áõ)¼º
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-antidote
    Ç×ÇØµ¶¾à.
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • anti-glomerular,basement menbrane nephritis
    Ç׻籸ü±âÀú¸·½Å¿°(ù÷Þêϳô÷Ðñî¼Ø¯ãìæú)
  • anti-i autoantibody
    Ç×-I ÀÚ°¡Ç×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • anti-immune body
    Ç׸鿪ü.
  • anti-infective
    Ç×°¨¿°¼º, Ç×°¨¿°¾à.
  • anti-infective
    1. Ç×°¨¿°¼º. 2. Ç×°¨¿°¾à.
  • anti-inflammatory
    Ç׿°Áõ¼º(ù÷æúñøàõ)ÀÇ.
  • anti-inflammatory
    Ç׿°(Áõ)¼º
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • anti-insulin
    Ç×Àν¶¸°.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plaque forming cell
    ÇöóÅ© Çü¼º ¼¼Æ÷(û¡à÷á¬øà)
  • plaque reduction method
    ÇöóÅ© °¨¼Ò¹ý(Êõá´Ûö)
  • plaque technique
    ÇöóÅ©¼ú(âú)
  • plaque titer
    ÇöóÅ© ÀûÁ¤(îêïÒ)°ª
  • plaque-type mutant
    ÇöóÅ©Çü(û¡) º¯ÀÌü(ܨì¶ô÷)
  • red plaque
    Àû»ö(îåßä) ÇöóÅ©
  • turbid plaque
    ȥŹ(ûèöú)Ç÷¹ÀÌÅ©
  • turbid plaque mutant
    ȥŹ(ûèöú)Ç÷¹ÀÌÅ© º¯ÀÌÁÖ(ܨì¶ñ»)
  • white plaque
    ÈØ Ç÷¹ÀÌÅ©
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TAT   1) Thematic Apperception Test; ÁÖÁ¦ Åë°¢ °Ë»ç
  2) (Equine) Tetanus Anti-Toxin; Ç×...
AIA allylisopropylacetamide; amylase inhibitor activity; anti-immunoglobulin antibody; anti-insulin anti...
AIF anemia-inducing factor; anti-inflammatory; anti-invasion factor
anti-PNM Ab anti-peripheral nerve myelin antibody
PRNT Plaque Reduction Neutrolization Test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PI Plaque Index
PII Plaque Index
PLI Plaque Index
PRN Plaque Reduction Neutralization
PRNT Plaque reduction neutralization tests
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • F1 anti-parental cytotoxicity
    F1 Ç× ¾çÄ£ ¼¼Æ÷ »óÇØ, F1 Ç× ¾çÄ£ ¼¼Æ÷ µ¶¼º
    in vivo¿¡¼­ F
  • F2 anti-parental cytotoxicity
    F2 Ç× ¾çÄ£ ¼¼Æ÷ »óÇØ
    in vitro¿¡¼­ F
  • atrophic large-plaque parapsoriasis
    À§Ã༺ ÆÇ
  • clear plaque mutation
    Åõ¸í ÇöóÅ© µ¹¿¬º¯ÀÌ
  • dental microbial plaque
    Ä¡¸é ±ÕÅÂ
    Ä¡¾Æ Ç¥¸é¿¡ ȹµæ ÇǸ·ÀÇ ¼®È¸È­·Î ÀÎÇØ ¾ß±âµÈ
  • dental plaque
    Ä¡ÅÂ
    ´Ù¾çÇÑ ¹ÚÅ׸®¾ÆÀÇ ¼ºÀåÀ» À§ÇÑ È¯°æÀÇ Á¦°øÀÌ µÇ´Â Ä¡¾Æ Ç¥¸é¿¡ Ä§ÂøµÇ¾îÁø Á×Àº »óÇǼ¼Æ÷¿Í ¹Â½Å, À½½Ä¹° Â±âÀÇ ¾ã°í ºÎµå·¯¿î ¸·. ÁÖ¿äÇÑ ¹«±â ¼ººÐÀº Ä®½·°ú ÀÎ ±×¸®°í ¼Ò·®ÀÇ ¸¶±×³×½·, œþ·ý, ³ªÆ®·ýÀÌ´Ù. À¯±â ±âÁúÀº ´Ù´çÁú, ´Ü¹éÁú, ź¼öÈ­¹°, ÁöÁú ±×¸®°í ´Ù¸¥ ¼ººÐÀÌ´Ù. Çöó±×
  • fibrous plaque
    ¼¶À¯¹Ý
  • flat plaque
    ÆíÆò ¹Ý
  • flat skin plaque
    ÆíÆò ÇǺΠ¹Ý
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ½ÃÇè, ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • moist plaque
    ÃàÃàÇÑ Ä¡ÅÂ
  • mottled plaque
    ¿ë±Õ ¹Ý
  • opaline plaque
    ´Ü¹é¼®¾ç ¹Ý
  • plaque control
    ġŠÁ¶Àý
  • plaque formation
    º´¼Ò ¹Ý Çü¼º, ÇöóÅ© Çü¼º
    ȹµæ ÇǸ·ÀÇ Çü¼º, ȹµæ ÇǸ·¿¡ ¼¼±ÕÀÇ ÃʱâºÎÂø, ¼¼±Õ¼º ġŰ¡ ¸î ÃþÀ¸·Î ÃàÀûµÇ¾î µÎ²¨¿öÁö´Â °úÁ¤À» ¸»ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
neuritic plaque <cell biology> Abnormal cluster of dead and dying nerve cells, other brain cells and protein.
Neuritic plaques are one of the characteristic structural abnormalities found in the brains of alzheimer patients. Upon autopsy, the presence of neuritic plaques andneurofibrillary tangles is used to positively diagnose Alzheimer's disease.
(22 May 1997)
dental plaque <dentistry> A soft, thin film of food debris, mucin and dead epithelial cells deposited on the teeth, providing the medium for the growth of various bacteria.
The main inorganic components are calcium and phosphorus with small amounts of magnesium, potassium and sodium, the organic matrix consists of polysaccharides, proteins, carbohydrates, lipids and other components.
Plaque plays an important aetiological role in the development of dental caries and periodontal and gingival diseases and provides the base for the development of materia alba, calcified plaque forms dental calculus.
(19 Mar 1998)
dental plaque index An index which scores the degree of dental plaque accumulation.
(12 Dec 1998)
fibrous plaque Thickened area of arterial intima with accumulation of smooth muscle cells and fibrous tissue (collagen etc.) produced by the fat laden smooth muscle cells. Below the thickening may be free extracellular lipid and debris that, if much necrosis is also present, is referred to as an atheroma.
(18 Nov 1997)
agent, anti-infective Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
anti- <prefix> A prefix meaning against, opposite or opposed to, contrary, or in place of, in relation to symptoms and diseases, curative.
Often used in composition in many English words. It is often shortened to ant-; as, antacid, antarctic.
Origin: Gr. against, opposite, instead of.
Source: Websters Dictionary
(20 Jun 2000)
anti-allergic agents Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells.
(12 Dec 1998)
anti-allergic and respiratory system agents A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system.
(12 Dec 1998)
anti-anxiety agents Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants.
(12 Dec 1998)
anti-arrhythmia agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
(12 Dec 1998)
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anti-basement membrane antibody Autoantibodies to renal glomerular basement membrane antigens.
(05 Mar 2000)
anti-basement membrane glomerulonephritis Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome.
(05 Mar 2000)
anti-basement membrane nephritis Glomerulonephritis produced by autologous or heterologous antibodies to the glomerular capillary basement membranes, the latter known as anti-kidney serum nephritis.
(05 Mar 2000)
anti-black-tongue factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á